Diligence memo · auto-generated · as of July 2, 2026

Sequence Bio

Sequence Bio: limited disclosed financing to assess.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Sequence Bio operates in Biotech / Pharma, based in St. John's, NL, Canada. Discovering the true signals of disease to power life-changing drugs.

Sub-sector tags: Genomics, Therapeutics, Drug discovery.

Capital & rounds (filed)filed

Sequence Bio has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.

Valuation (modeled)modeled

No modeled valuation — too little disclosed financing to estimate one.

Financing rhythm & timingmixed

Not enough dated financing history to read a financing rhythm.

Comparablesmixed

Capital scale ranks ahead of 5% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 5% of those peers.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.